BMY Today - Aug 12: Merger Talk Fizzles Out
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
BMY Today - Aug 12: Merger Talk Fizzles Out
-
Letto da:
-
Di:
So, here’s the scoop. There’s been some chatter about a possible merger with AstraZeneca. But honestly, Wall Street isn't buying it. That talk seems to have fizzled out, and investors are feeling a bit skeptical. You know how it goes—when there’s uncertainty, people tend to hit the sell button fast. BMY's stock underperformed compared to its competitors today, which isn’t a great look. It’s like showing up to a party where everyone else is dressed to impress, and you’re in sweats. Yeah, that one stung.
And get this—Handelsbanken Fonder sold a ton of shares, almost half a million. That’s a pretty big move and probably shook some confidence. On the flip side, Wedge Capital is actually raising their stake in BMY, but that didn’t seem to help the stock much today. It’s like a mixed bag of vibes out there.
Now, on the horizon, Schrödinger, a company that's been in bed with BMY, just announced a solid Q2 profitability and their stock shot up over 19%. That could mean some good news for BMY down the line, but who knows? The market’s a wild ride.
So, to wrap it up, BMY had a pretty lackluster day, caught in the crossfire of merger talks that aren’t gaining any traction. It’s definitely a stock to keep an eye on, but remember, this is just for info and entertainment. Always do your own research before making any moves. Catch you later!
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione